119-S-545 Journalist Public Summary
119 · S 545 Combating Illicit Xylazine Act
A bipartisan Senate bill would place xylazine—the veterinary sedative increasingly found in the illicit drug supply—on Schedule III, add tracking and reporting tools, and set penalties while carving out access for veterinarians; it has cleared the Senate Judiciary Committee and awaits a floor vote. (congress.gov)
Public Summary — S. 545, Combating Illicit Xylazine Act (119th Congress)
Headline Summary: The bill would classify xylazine as a Schedule III controlled substance nationwide while preserving legitimate veterinary use and adding tools to track, penalize, and report illicit trafficking. (congress.gov)
What It Does: S. 545 adds xylazine to Schedule III of the Controlled Substances Act; clarifies who may legally possess it for animal care; phases in registration, labeling, and security requirements; expands DEA’s ARCOS tracking to include xylazine; directs the U.S. Sentencing Commission to set appropriate penalties; and requires DEA/FDA reports to Congress on prevalence, diversion, and potential analogues. (congress.gov)
Why It Matters: Xylazine, a veterinary sedative not approved for people, has been turning up in the illicit drug supply—often alongside fentanyl—contributing to severe sedation and hard‑to‑treat wounds; federal analysts have flagged it as an emerging threat and outlined regulatory trade‑offs Congress should weigh. (dea.gov)
Who’s For It:
- American Veterinary Medical Association (AVMA): Supports scheduling with protections to keep xylazine available for animal care and to improve supply‑chain tracking. (avma.org)
- Law enforcement groups and a bipartisan coalition of 41 state attorneys general: Argue the bill gives DEA needed tools to track manufacturing/diversion and to target traffickers. (judiciary.senate.gov)
- Bipartisan congressional sponsors in both chambers: Frame the bill as cracking down on illicit use while safeguarding veterinary access. (judiciary.senate.gov)
Who’s Against It:
- Drug Policy Alliance and allied public‑health/civil‑rights groups: Warn that scheduling could criminalize people who use drugs, chill research, and distract from health‑based responses. (drugpolicy.org)
- Some stakeholders in animal care raise concerns about added regulatory burdens if DEA registration and recordkeeping are required for routine veterinary use. (congress.gov)
What’s Next: As of April 15, 2026, S. 545 was reported out of the Senate Judiciary Committee and placed on the Senate calendar (Calendar No. 372). The next step is a Senate floor vote; if it passes, it would move to the House (where a companion bill, H.R. 1266, is pending) or to conference if the chambers pass differing versions. (congress.gov)
Discussion